AMT holds the commercialization rights to the AIP gene therapy (AMT-021).
Under this grant, AMT expects to obtain EUR1.1m, which will cover almost 75% of AMT’s overall development cost of the product to complete Phase I/II study in humans.
With the support of the all the Aipgene partners, AMT anticipates AIP patient enrollment in a clinical trial to begin in 2012.
AMT CEO Jorn Aldag said this grant allows them to prioritize the development of our AIP gene therapy program for this progressive and devastating disease within AMT’s pipeline, as well as initiating the next step in advancing a potentially more effective, long-term treatment for patients.